17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work
in different ways to stop tumor cells from dividing so they stop growing or die.
17-N-allylamino-17-demethoxygeldanamycin may also stop the growth of tumor cells by blocking
the enzymes necessary for their growth.
PURPOSE: This phase II trial is studying how well 17-N-allylamino-17-demethoxygeldanamycin
works in treating patients with metastatic kidney cancer.